ALNY supply chain intelligence for Alnylam Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Alnylam Pharmaceuticals, Inc. (ALNY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REGENERON | REGENERON | 90% | In November 2022, Regeneron exercised its right under the C5 Co-Co Collaboration Agreement to opt-out of the further development and commercialization of cemdisiran monotherapy. |
| ROCHE | ROCHE | 85% | As of the Effective Date, we identified the following promises in the Roche Agreement that were evaluated under the scope of Accounting Standards Codification, or ASC, Topic 606, Revenue from Contrac… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: usiness and financial condition, including, among other things: • delays to the development timelines for our product candidates; • interruption of supply res… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: t of our agreement with them. Any of our drug candidates, therefore, may be subject to competition with a drug candidate under development by a customer. Ther… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: nt of certain development, regulatory and sales events. We will also reimbur… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NTLA g… |
| NVS | Novartis AG | 72% | Reciprocal relationship from NVS graph: w and Prospects—Overview—Our strategy.” In 2024, Novartis achieved net sales from continuing operations of USD 50.3 billion, and net income from continuing ope… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSE… |
| PEPG | PepGen Inc. | 72% | Reciprocal relationship from PEPG graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from PEPG g… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN g… |
| RNA | Atrium Therapeutics, Inc. | 72% | Reciprocal relationship from RNA graph: ss of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies; • our ability to obtain and maintai… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SRPT g… |
| TNYA | Tenaya Therapeutics, Inc. | 72% | Reciprocal relationship from TNYA graph: occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Contract Li… |
| VEEV | Veeva Systems Inc. | 72% | Reciprocal relationship from VEEV graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VEEV graph: Consulting provides strategic consulting services and solutions that are oft… |
| VIR | Vir Biotechnology, Inc. | 72% | Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VIR grap… |
| VOR | Vor Biopharma Inc. | 72% | Reciprocal relationship from VOR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VOR graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from VOR grap… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 85% | bal, strategic collaboration with Regeneron Pharmaceuticals, Inc., or Regeneron, to discover, develop and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic targe… |
| REGN | Regeneron Pharmaceuticals, Inc. | 85% | Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from REGN g… |
| AZN | AstraZeneca PLC | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from AZN grap… |
| BNTX | BioNTech SE | 72% | Reciprocal relationship from BNTX graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from BNTX graph: usiness and financial condition, including, among other things: • delays to … |
| DYN | Dyne Therapeutics, Inc. | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financ… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IBIO g… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: ible to receive tiered royalties up to 30 percent on net sales. From incepti… |
| LLY | Eli Lilly and Company | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financ… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and finan… |
| NTLA | Intellia Therapeutics, Inc. | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| NVO | Novo Nordisk A/S | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVO graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, whi… |
| NVS | Novartis AG | 72% | Reciprocal relationship from NVS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVS grap… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from NVSE… |
| SLN | Silence Therapeutics plc | 72% | Reciprocal relationship from SLN graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financ… |
| SLN | Silence Therapeutics plc | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | yasthenia gravis and geographic atrophy. In August 2025, Regeneron announced that cemdisiran monotherapy met the primary and key secondary endpoints in the Phase 3 NIMBLE clinical trial in generalize… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the risk of employee fraud or other misconduct. … |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and finan… |
| VIR | Vir Biotechnology, Inc. | 72% | , the lead party will be responsible for all costs and expenses incurred in connection with the development and commercialization of the collaboration products under the applicable co-co collaboratio… |
| VIR | Vir Biotechnology, Inc. | 72% | Reciprocal relationship from VIR graph: Reciprocal relationship from ALNY graph: , the lead party will be responsible for all costs and expenses incurred in connection with the development and commer… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinica… |
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 62% | antially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended December 31, 2025, which were included in our Annual Report on Form … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ALNY-DEBT-7692 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| ALNY-DEBT | Debt stack $677.7M | 90% | Market cache reports total debt of $677.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 10,444,908; value $3.46T; as of 2026-03-31. |
| ALNY-OWNER-FMR-LLC | FMR LLC | 95% | 13F/ownership overlay lists FMR LLC; shares held 14,579,166; ownership 10.90%; value $4.82T; as of 2026-03-31. |
| ALNY-OWNER-CAPITAL-RESEARCH-GLOBAL-INVESTORS | Capital Research Global Investors | 95% | 13F/ownership overlay lists Capital Research Global Investors; shares held 9,471,181; value $3.13T; as of 2026-03-31. |
| ALNY-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC | VANGUARD PORTFOLIO MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 6,491,280; value $2.15T; as of 2026-03-31. |
| ALNY-OWNER-JPMORGAN-CHASE-CO | JPMORGAN CHASE & CO | 95% | 13F/ownership overlay lists JPMORGAN CHASE & CO; shares held 6,323,752; value $2.00T; as of 2026-03-31. |
| ALNY-OWNER-CAPITAL-WORLD-INVESTORS | Capital World Investors | 95% | 13F/ownership overlay lists Capital World Investors; shares held 10,802,348; value $3.57T; as of 2026-03-31. |
| ALNY-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 11,893,412; value $3.94T; as of 2026-03-31. |
| ALNY-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 3,322,698; value $1.10T; as of 2026-03-31. |
| ALNY-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 2,698,899; value $1.05T; as of 2026-03-31. |
| ALNY-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEMENT-INC | T. Rowe Price Investment Management, Inc. | 95% | 13F/ownership overlay lists T. Rowe Price Investment Management, Inc.; shares held 5,193,324; value $1.7B; as of 2026-03-31. |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Tanguler Tolga | EVP, Chief Commercial Officer | option_exercise | 1666 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Poulton Jeffrey V. | EVP, Chief Financial Officer | option_exercise | 5724 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Yvonne Greenstreet | Chief Executive Officer | option_exercise | 17763 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | option_exercise | 158 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Garg Pushkal | EVP Chief R&D | sell | 2242 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Yvonne Greenstreet | Chief Executive Officer | sell | 6958 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Garg Pushkal | EVP Chief R&D | sell | 2242 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Poulton Jeffrey V. | EVP, Chief Financial Officer | sell | 2242 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Yvonne Greenstreet | Chief Executive Officer | sell | 6958 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Tolga Tanguler | EVP, Chief Commercial Officer | sell | 220 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | SUPRAN BRYAN | EVP, CLO and Secretary | sell | 1758 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Garg Pushkal | EVP Chief R&D | sell | 220 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | sell | 644 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | sell | 644 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Tolga Tanguler | EVP, Chief Commercial Officer | sell | 220 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Poulton Jeffrey V. | EVP, Chief Financial Officer | sell | 405 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Garg Pushkal | EVP Chief R&D | sell | 220 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Arbuckle Stuart A | 10% Owner | option_exercise | 3279 shares |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Stuart A. Arbuckle | Officer |
| ALNY | Alnylam Pharmaceuticals, Inc. | 82% | Arbuckle Stuart A | 10% Owner | option_exercise | 3279 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| IBIO | iBio, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| SNYNF | Sanofi | 100.00 | 1 | ['customer'] |
| BNTX | BioNTech SE | 100.00 | 1 | ['customer', 'supplier'] |
| GIFOF | Grifols, S.A. | 100.00 | 2 | |
| NVS | Novartis AG | 100.00 | 1 | ['customer', 'supplier'] |
| SLN | Silence Therapeutics plc | 100.00 | 1 | ['customer'] |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer'] |
| SLGL | Sol-Gel Technologies Ltd. | 100.00 | 2 | |
| HLNCF | Haleon plc | 100.00 | 2 | |
| GIKLY | Grifols, S.A. | 100.00 | 2 | |
| LQDA | Liquidia Corporation | 100.00 | 2 | |
| SRPT | Sarepta Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| RNA | Atrium Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| TEVJF | Teva Pharmaceutical Industries Limited | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer'] |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| COLL | Collegium Pharmaceutical, Inc. | 100.00 | 2 | |
| IONS | Ionis Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |